Kemmx Corporation is a start-up, biotechnology company pioneering the development and commercialization of targeted analgesics for chronic pain. Their topical analgesic formulations provide long lasting pain relief with minimal side effects.
Leviathan proposes a next-generation tool that will make it possible to distinguish and examine heterogeneous states among suspension cells in situ, with the potential for a significant increase in sensitivity, selectivity, resolution, and scalability over current technology.
Pure MHC focuses on HLA related immunology tools for vaccine development and immunotherapy validation.
GG Companies develops a powerful arthritis rub, a topical herbal gel used to soothe painful areas.
PreDENT has developed a vaccine to help prevent gingivitis and periodontal disease in pets?that produces significant pain and possibly even fatal damage to an animal?s organs.
Advance Research Chemicals, Inc. offers basic and advanced chemical applications and services in a wide array of industries including military defense,?semiconductors, battery materials, pharmaceuticals, medical devices, automotive components, textiles, agricultural solutions, surfactants and industrial cleaners.
Charlesson is an ocular pharmaceutical company that is developing therapeutics for various eye diseases, including wet and dry Age-related Macular Degeneration (AMD), Diabetic Retinopathy (DR), and Uveitis.
The Lupus Multiplex Registry and Repository is finding the genes that cause lupus (also known as SLE or Systemic Lupus erythematosus). It works with families with one or more living lupus patients from across the US, Canada, Puerto Rico and the Virgin Islands, utilizing the genetic link between blood relatives to locate responsible genes.
EpimedX, LLC is a biotechnology company that was founded in 2011 with the mission to develop Gene Regulation Therapy? ? a promising technology that is expected to provide a safe, cost-effective, and permanent treatment for sickle cell disease, beta-thalassemia, and malaria without dangerous or harmful side effects.
Pamlico Biopharma has developed personalized, targeted human antibody therapeutics against severe pneumonia that were created using patent-pending methodology from the Oklahoma Medical Research Foundation.
A subsidiary of Core Oncology, Mills Biopharmaceuticals, LLC (Mills) manufactures ProstaSeed? Iodine 125 brachytherapy seeds for the treatment of prostate cancer. Mills’ state-of-the-art 25,000 square foot manufacturing facility features highly automated machines and advanced manufacturing systems.
Synereca Pharmaceuticals addresses the growing problem of bacterial resistance to current antibiotics by developing orally active drugs that restore or increase the effectiveness of existing antibiotics.
Heparinex is a biotechnology company focused on the development of novel recombinant synthesis of heparinoid compounds for various markets including anticoagulation, biomaterials, and cellular modulation applications.
Moleculera Labs provides personalized clinical testing services for individuals suspected of suffering from PANDAS/PANS, which are treatable neurologic conditions that may be associated with motor tics, obsessive compulsive disorders (OCD) and sometimes Autism Spectrum Disorders.
Choncept?s scientific innovation is focused on development of new technology to produce chondroitin from fermentation of recombinant bacteria to replace the current chondroitin source of beef and other animal by-products.
Otologic Pharmaceutics, Inc. is an organization formed specifically to commercialize promising technologies that address novel pharmacological solutions for hearing and balance health.
DermaMedics is a skin care company that specializies in the discovery of technologies for the dermatology market.
Cassion Biotech has developed a bio-superior drug delivery system, HEPylation ? System, which uses a patented composition designed to improve the performance of many powerful drug compounds in terms of safety, tolerability, efficacy, and quality.
Biolytx Pharmaceuticals develops a novel antibiotic peptide for use in treatment of serious hospital-acquired infections, including those resistant to current antibiotics.
Selexys is a development stage biopharmaceutical company focused on the treatment of inflammatory and thrombotic diseases. ?The company has developed antibodies that block recruitment of white blood cells to activated endothelium and platelets. ?